PL400309A1 - Kwasy nukleinowe, proteiny oraz przeciwciala BTL-II - Google Patents

Kwasy nukleinowe, proteiny oraz przeciwciala BTL-II

Info

Publication number
PL400309A1
PL400309A1 PL400309A PL40030903A PL400309A1 PL 400309 A1 PL400309 A1 PL 400309A1 PL 400309 A PL400309 A PL 400309A PL 40030903 A PL40030903 A PL 40030903A PL 400309 A1 PL400309 A1 PL 400309A1
Authority
PL
Poland
Prior art keywords
btl
antibodies
proteins
nucleic acids
methods
Prior art date
Application number
PL400309A
Other languages
English (en)
Inventor
Peter R. Baum
Sabine S. Escobar
Joanne L. Viney
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corporation filed Critical Immunex Corporation
Publication of PL400309A1 publication Critical patent/PL400309A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)

Abstract

Wynalazek dostarcza wyodrebnione mysie proteiny BTL-II, kwasy nukleinowe, przeciwciala, antagonistów oraz agonistów, a takze sposoby ich wytwarzania oraz zastosowania. Zapewniono sposoby diagnostyczne, sposoby skriningu oraz sposoby terapeutyczne oparte na zastosowaniu kompozycji wedlug wynalazku. Przykladowo, kompozycje wedlug wynalazku mozna stosowac w diagnostyce i terapii chorób zapalnych jelita grubego oraz w celu wzmacniania odpowiedzi immunologicznej w blonie sluzowej na antygen.
PL400309A 2002-12-23 2003-12-19 Kwasy nukleinowe, proteiny oraz przeciwciala BTL-II PL400309A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43618502P 2002-12-23 2002-12-23
US52529803P 2003-11-26 2003-11-26

Publications (1)

Publication Number Publication Date
PL400309A1 true PL400309A1 (pl) 2013-10-14

Family

ID=32685440

Family Applications (2)

Application Number Title Priority Date Filing Date
PL379564A PL379564A1 (pl) 2002-12-23 2003-12-19 Kwasy nukleinowe, proteiny i przeciwciała BTL-II
PL400309A PL400309A1 (pl) 2002-12-23 2003-12-19 Kwasy nukleinowe, proteiny oraz przeciwciala BTL-II

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL379564A PL379564A1 (pl) 2002-12-23 2003-12-19 Kwasy nukleinowe, proteiny i przeciwciała BTL-II

Country Status (9)

Country Link
US (4) US7244822B2 (pl)
EP (1) EP1585760B1 (pl)
JP (1) JP4671694B2 (pl)
AU (1) AU2003299687B2 (pl)
CA (1) CA2509999A1 (pl)
ES (1) ES2391949T3 (pl)
MX (1) MXPA05006535A (pl)
PL (2) PL379564A1 (pl)
WO (1) WO2004058986A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011237365B2 (en) * 2010-04-09 2015-01-29 Amgen Inc. BTNL9 proteins, nucleic acids, and antibodies and uses thereof
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
JP5830048B2 (ja) * 2013-03-15 2015-12-09 信越化学工業株式会社 チタン含有レジスト下層膜形成用組成物及びパターン形成方法
US11661447B2 (en) 2017-08-03 2023-05-30 The Cleveland Clinic Foundation Human β2-glycoprotein I expression
CA3090305A1 (en) * 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
WO2023004344A1 (en) * 2021-07-20 2023-01-26 Regeneron Pharmaceuticals, Inc. Butyrophilin-like 2 for treating inflammatory disorders
CN114437234A (zh) * 2021-12-28 2022-05-06 四川省医学科学院·四川省人民医院 Btnl2重组蛋白及其制备方法与在制备用于治疗炎症性肠病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
WO2001053836A2 (en) 2000-01-24 2001-07-26 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of prostate cancer
DE10032529A1 (de) 2000-06-30 2002-02-07 Epigenomics Ag Diagnose von bedeutenden genetischen Parametern innerhalb des Major Histocompatibility Complex (MHC)
CA2422215A1 (en) * 2000-09-20 2002-03-28 Amgen Inc. B7-like molecules and uses thereof
EP1334113A4 (en) 2000-10-20 2007-08-08 Expression Diagnostics Inc EVALUATION OF LEUCOCYTAIRE EXPRESSION LEVEL
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
AU2003210309A1 (en) 2002-02-20 2003-09-09 Universiteit Gent Method of modulating e-cadherin mediated cell adhesion

Also Published As

Publication number Publication date
EP1585760A2 (en) 2005-10-19
AU2003299687A1 (en) 2004-07-22
WO2004058986A3 (en) 2005-06-23
US8674078B2 (en) 2014-03-18
US7244822B2 (en) 2007-07-17
ES2391949T3 (es) 2012-12-03
EP1585760B1 (en) 2012-08-08
US20120258097A1 (en) 2012-10-11
WO2004058986A2 (en) 2004-07-15
US20090142801A1 (en) 2009-06-04
JP2006525786A (ja) 2006-11-16
AU2003299687B2 (en) 2010-01-21
US20100330104A1 (en) 2010-12-30
US8173603B2 (en) 2012-05-08
CA2509999A1 (en) 2004-07-15
JP4671694B2 (ja) 2011-04-20
US7709618B2 (en) 2010-05-04
US20040209289A1 (en) 2004-10-21
PL379564A1 (pl) 2006-10-16
EP1585760A4 (en) 2006-06-21
MXPA05006535A (es) 2005-09-08

Similar Documents

Publication Publication Date Title
EA019476B9 (ru) АНТИТЕЛА ПРОТИВ IL-23p19 И ИХ ПРИМЕНЕНИЕ
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DE60220719D1 (de) Antikörper gegen das muc18-antigen
EP1539228A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
CY1112507T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β
EA200702374A1 (ru) Анти-il-6 антитела, композиции, способы их получения и применения
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
ATE385806T1 (de) Fusionsproteine
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
EP2322203A3 (en) Compositions and methods for the treatment of immune related diseases
NO20056236L (no) Behandling med anti-VEGF-antistoffer
AT500379B1 (de) Tau-proteine
PE20030473A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
EP1539251A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL DISEASES WITH ANGIOGENESIS
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
BRPI0712273A2 (pt) Anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
ATE402958T1 (de) Antagonisten des ige-rezeptors
NO20033115D0 (no) Peptid-baserte forbindelser
WO2004058986A3 (en) Btl-ii nucleic acids, proteins, and antibodies
BR0312483A (pt) Anticorpos e seus usos

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)